April 7 (Reuters) - The U.S. announced a 5.06% average increase in the government's final reimbursement rates for 2026 Medicare Advantage health plans run by private insurers, more than double the increase it proposed in January.
The rate the U.S. government pays to private health insurers to manage healthcare under Medicare for people aged 65 and older or with disabilities, influences the monthly premiums they charge, plan benefits they offer and, ultimately, their profits.
Higher rates will benefit large U.S. health insurers, including UnitedHealth Group and Humana, which have been grappling with steep medical costs related to government-backed Medicare and Medicaid plans.
Shares of Humana jumped 10.7% in premarket trading on Tuesday, and those of CVS Health added 6.6%. Elevance Health shares jumped 6.9% and UnitedHealth rose 5.8% in premarket trading.
The final rate indicates "visible evidence of Trump administration's support for MA program," said Bernstein analyst Lance Wilkes.
The Centers for Medicare & Medicaid Services (CMS), which oversees Medicare and Medicaid health insurance programs, had earlier proposed a 2.2% increase in 2026 payments. Last year, the government announced a 0.2% decline in the reimbursement rates for 2025.
The CMS said the rate change primarily takes into account additional data on the increase in costs for the insurers, including payment data through the fourth quarter of 2024.
"We're encouraged that CMS is supportive of this important program," a spokesperson for CVS said, adding that 88% of its Medicare Advantage members are currently enrolled in CMS' highly rated plans with 4 stars or more.
As insurers "review the new policies released in the last two days, they will continue to focus on helping seniors stay healthy, closing gaps in care and supporting those with chronic illness," said industry lobbying group America's Health Insurance Plans.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。